Provided By PR Newswire
Last update: Dec 26, 2024
USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Dec. 26, 2024 /PRNewswire/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively targeting cancer cells while preserving healthy tissue. These innovations underscore the relentless pursuit of breakthroughs in oncology to enhance patient outcomes. Among the key players driving recent progress in the field are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Erasca, Inc. (NASDAQ: ERAS), Allogene Therapeutics, Inc. (NASDAQ: ALLO), Context Therapeutics Inc. (NASDAQ: CNTX), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).
Read more at prnewswire.com1.41
-0.05 (-3.42%)
2.17
-0.08 (-3.77%)
0.814
+0.02 (+3.04%)
0.7256
-0.01 (-1.79%)
9.28
-1.07 (-10.34%)
Find more stocks in the Stock Screener